HAYWARD, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the third quarter ended September 30, 2016.
Recent Developments and Business Highlights:
Blisibimod for the treatment of Systemic Lupus Erythematosus (“SLE”)
